Axiom Biopharma Announces Its Intent to Acquire the Assets of CellMark
View as PDF
Axiom Biopharma, a leading research and development-based biopharmaceutical company, announces that it has agreed to acquire the assets of CellMark Biopharma, LLC, a Medical Nutrition company with leading products CellAssure and Cognify composed of ingredients clinically proven to advance cellular health. --
Axiom Biopharma, a leading research and development-based biopharmaceutical company, announces that it has agreed to acquire the assets of CellMark Biopharma, LLC, a Medical Nutrition company with products composed of ingredients clinically proven to advance cellular health.
Under the terms of the agreement, Axiom will acquire the assets of the business/ product units - CellAssure and Cognify, and retain several members of the Executive team, support and field personnel. Axiom Biopharma is providing a significant opportunity to continue building on CellMark's successful nationwide launch of CellAssure, a medical nutrition supplement specifically designed to advance cellular health, and Cognify, the first of its kind cognitive enhancer specifically formulated for what's commonly referred to as 'brain fog', and play a leading role in the medical nutrition and dietary market space.
"We are excited about the new opportunities the Axiom platform provides as we continue to grow our presence in the 'Medical Nutrition' sector", stated Axiom Biopharma's CEO, Craig Pisaris-Henderson. "Further, we have several additional announcements as we enter 2017 and expand our team and product distribution through several new partnerships."
With the initial launch of CellAssure and Cognify, CellMark was able to gain traction in most of North America. With the combined resources of Axiom and CellMark, Axiom expects to expand of all 50 states and begin distribution internationally in the second half of 2017.
"Our passion to find solutions for global unmet dietary and nutritional needs fuels our R&D efforts to develop products that have the highest potential to positively impact global consumers in the medical nutrition sector", stated Erica Boliek, Axiom Biopharma's Chief of Research and Development.
Axiom Biopharma also announced it will be moving forward immediately in pursuit of conducting clinical trials consisting of people looking to increase lean muscle mass and advance their cellular health.
About Axiom Biopharma, Inc.:
Axiom Biopharma is a leading research and development-based biopharmaceutical company that formulates, manufactures, and distributes 'Medical Nutrition' supplements developed to help with specific dietary issues not previously met by other known dietary supplements.
For more information, please visit https://www.AxiomBiopharma.com
Name: Cole Peacock
Organization: AXIOM BIOPHARMA
Address: 1591 Hayley Lane, Fort Myers, 33907 United States
Release ID: 160003
Recent Press Releases By The Same User
Agarwood Essential Oil Market Expected to Grow at CAGR 4.2% During 2016 to 2022 (Fri 2nd Jun 17)
Cyber Weapon Market by Type, Product, Application, Region, Outlook and Forecast to 2022 (Fri 2nd Jun 17)
Landscaping and Gardening Expert Trevor McClintock Launches New Locally Optimized Website (Fri 2nd Jun 17)
Sleep apnea devices Market is Evolving At A CAGR of 7.5% by 2022 (Fri 2nd Jun 17)
Agriculture Technology Market 2017 Global Analysis, Opportunities and Forecast to 2022 (Fri 2nd Jun 17)
Global VR Helmet Market by Manufacturers, Technology, Type and Application, Forecast to 2022 (Fri 2nd Jun 17)